BUSINESS/FINANCE NEWS
Setup News Ticker
   BUSINESS/FINANCE NEWS
Searching for 'shares rise'. (Return)

MarketWatch MarketPulseDec 13, 2019
Amarin gets FDA approval for new Vascepa use, U.S. shares gain in late trading
Amarin Corp. received U.S. approval to market its drug Vascepa to reduce the risk of cardiovascular events in people with high triglyceride levels, according to the Food and Drug Administration late Friday. U.S.-traded shares were halted at $24.12 at 10:06 a.m. Eastern, hours before the announcement; when they resumed trading at 5:30 p.m., they gained more than 2% in after-hours action. "Vascepa is the first FDA approved drug to reduce cardiovascular risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy," the agency said in a statement. Vascepa was originally approved in 2012 to treat patients with severely high triglyceride levels. ADRs of Dublin-based Amarin are up 77% year-to-date, compared with a 26% rise in the S&P 500 index

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.


TRENDING TAGS
Tradedeal China Stocks Trump US-China
Dealtrade China Stocks Trump US-China
Chinatrade deal US-China Trump Stocks
TrumpTrade Deal China Supreme Court
StocksTrade deal China progress reveals
Yearnext Year-End 13-year-old Barnard boy
planPG&E bankruptcy rejects governor California
businessHow UK Palantir deepens Pentagon
GovernorPG&E California bankruptcy plan rejects
PG&E

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2019 CEOExpress Company LLC